XTLBNasdaqPharmaceutical Preparations
XTL BIOPHARMACEUTICALS LTD
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Jun 30, 2026
$1.96−0.00 (-0.01%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Xtl Biopharmaceuticals statistics
Financials through Dec 31, 2024, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $18.55M | $164.85M |
| Enterprise Value | $18.31M | $87.06M |
| PS Ratio | 41.12 | 3.60 |
Enterprise value
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 40.60 | 2.43 |
Income (trailing twelve months)
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| Revenue | $451.00K | $57.94M |
| Gross Profit | $3.00K | $90.47M |
| Operating Income | -$2.17M | -$21.44M |
| Pretax Income | -$1.16M | -$14.45M |
| EBITDA | -$2.17M | -$16.91M |
| EPS (Diluted) | -$0.00 | -$0.83 |
Margins
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 0.67% | 52.3% |
| Operating Margin | -481.6% | -44.5% |
| Pretax Margin | -256.5% | -13.0% |
| EBITDA Margin | -481.6% | -31.3% |
| FCF Margin | -370.7% | -8.85% |
Returns
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | -34.2% | -37.8% |
Balance sheet
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $371.00K | $62.42M |
| Total Debt | $138.00K | $120.13M |
| Net Cash (Debt) | $233.00K | $15.68M |
| Net Cash Per Share | $0.00 | $0.66 |
| Working Capital | -$867.00K | $75.77M |
Financial position
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 0.61 | 3.30 |
| Quick Ratio | 0.21 | 2.39 |
| Interest Coverage | -77.57 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.62M | -$12.35M |
| Capital Expenditures | -$54.00K | -$1.06M |
| Free Cash Flow | -$1.67M | -$20.28M |
| FCF Per Share | -$0.00 | -$0.42 |
Efficiency
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.05 | 0.38 |
| Revenue Per Employee | $150.33K | $398.96K |
| Employee Count | 3 | 74 |
Dividends and yields
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| FCF Yield | -9.02% | -9.07% |
Shares
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 946,243,000 | 58,179,650 |
| Shares Change (YoY) | 29.2% | 11.1% |
| Float | 946,243,000 | 49,173,100 |
| Shares Held by Insiders | 0.00% | 11.6% |
| Shares Held by Institutions | 0.00% | 59.4% |
Taxes
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$130.00K | $91.50K |
Scores
| Measure | Xtl Biopharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -23.37 | -0.24 |
Calculated by StockData from Xtl Biopharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.